98%
921
2 minutes
20
Protraction of mandibular bilateral second molars to substitute for the extracted first molars is challenging in clear aligner treatment due to biological and biomechanical limitations. This case report presents a 28-year old female patient with poor prognoses for the mandibular bilateral first molars, a mesially impacted mandibular left third molar, and crowding in both the upper and lower arches. After the extraction of mandibular bilateral first molars, long-distance mandibular molar protraction was achieved using clear aligners with a novel protraction appliance, "the long arm hook". At the end of the treatment, a Class I canine and molar relationship and good root parallelism were achieved. The combination of long arm hooks and clear aligners has proven to be clinically effective for the protraction of mandibular molars, thereby expanding the scope of clear aligner treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ortho.2025.101029 | DOI Listing |
Obesity (Silver Spring)
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Objective: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods: This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m or ≥ 27 kg/m with ≥ 1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.
J Obstet Gynaecol
December 2025
Division of Minimally Invasive Gynaecologic Surgery, Baylor College of Medicine, Houston, Texas, USA.
Background: Robotic single-port transvaginal natural orifice transluminal endoscopic surgery (RSP-vNOTES) is an emerging minimally invasive approach that combines the advantages of robotic surgery with scarless transvaginal access. Its application in gynecologic oncology remains limited, particularly for omentectomy during ovarian cancer staging.
Methods: We present the case of a 45-year-old woman with an ovarian granulosa cell tumor (GCT) who underwent supplemental staging surgery following unilateral oophorectomy.
J Clin Pharmacol
September 2025
CSL Behring LLC, King of Prussia, PA, USA.
Garadacimab is a novel, fully human, anti-activated factor XII monoclonal antibody approved for long-term prophylaxis of patients with hereditary angioedema. This open-label, parallel-group, Phase 1, single-center, bridging study in healthy adults (18-55 years of age) characterized the pharmacokinetics and safety of a single 200 mg subcutaneous injection of garadacimab administered via autoinjector/pre-filled pen (AI/PFP) compared with the pre-filled syringe (PFS) used in previous studies. The aim of the study was to bridge the understanding of the PK and safety of garadacimab between PFS and AI/PFP modes of administration.
View Article and Find Full Text PDFBMJ Open
September 2025
Johns Hopkins University School of Nursing, Baltimore, Maryland, USA.
Introduction: Low-income adults with disabilities experience disproportionately high rates of food insecurity and preventable healthcare utilisation. The Supplemental Nutrition Assistance Program (SNAP) can reduce food insecurity and improve health, but there are accessibility gaps in the SNAP enrolment process. Existing outreach and enrolment assistance programmes have been shown to boost SNAP enrolment, but their health effects are understudied.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
September 2025
Department of Radiation Oncology, Washington University School of Medicine in Saint Louis, Saint Louis, MO, USA. Electronic address:
Purpose: This study evaluates the long-term outcomes of single-fraction, high-gradient partial breast irradiation (BreaStBRT) as a post-operative treatment in patients with early-stage, hormone-positive breast cancer. It aims to assess acute and late treatment-related toxicity, cosmesis, patient-reported quality of life (QoL), and oncologic outcomes.
Materials And Methods: Single-institution, single-arm, phase II prospective trial included post-menopausal women ≥50 years old with early-stage, hormone-positive breast cancer treated with breast-conserving therapy (BCT) followed by BreaStBRT.